Could These Clinical Results Mean Profit for AbbVie Shareholders?
Earlier this month, pharma giantAbbVie(NYSE:ABBV) reported the results from its phase 3 clinical trial testing of atogepant for the preventive treatment of migraine in adults who met the criteria for episodic migraine.
Let’s take a look at why the results…
